TY - JOUR
T1 - New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation
AU - Japan ABPM Research Program
AU - Asano, Koichiro
AU - Hebisawa, Akira
AU - Ishiguro, Takashi
AU - Takayanagi, Noboru
AU - Nakamura, Yasuhiko
AU - Suzuki, Junko
AU - Okada, Naoki
AU - Tanaka, Jun
AU - Fukutomi, Yuma
AU - Ueki, Shigeharu
AU - Fukunaga, Koichi
AU - Konno, Satoshi
AU - Matsuse, Hiroto
AU - Kamei, Katsuhiko
AU - Taniguchi, Masami
AU - Shimoda, Terufumi
AU - Oguma, Tsuyoshi
N1 - Funding Information:
This study was funded by the Research Grant on Allergic Disease and Immunology , from the Japan Agency for Medical Research and Development , under the grant numbers JP18ek0410026 and JP20ek0410055 .
Funding Information:
Disclosure of potential conflict of interest: K. Asano reports grants from Japan Agency for Medical Research and Development; personal fees from Thermo Fisher Diagnostics KK during the conduct of the study; personal fees from AstraZeneca KK GlaxoSmithKline KK, and Teijin Pharma Ltd; grants and personal fees from Nippon Boehringer Ingelheim Co, Ltd and Novartis Pharma KK; and grants and personal fees from Sanofi SA outside the submitted work. A. Hebisawa reports grants from Japan Agency for Medical Research and Development during the conduct of the study. J. Suzuki reports grants from Japan Agency for Medical Research and Development during the conduct of the study. Y. Fukutomi reports grants from Japan Agency for Medical Research and Development during the conduct of the study; personal fees from Thermo Fisher Diagnostics KK, Torii Pharmaceutical Co, Ltd, and Kyorin Pharmaceutical Co, Ltd; grants and personal fees from Novartis Pharma KK; and grants from GlaxoSmithKline KK outside the submitted work. S. Ueki reports grants and personal fees from Novartis Pharma KK, AstraZeneca KK, and Sanofi; grants from Japan Allergy Foundation, Charitable Trust Laboratory Medicine Research Foundation of Japan, Japan Society for the Promotion of Science Kakenhi, Maruho Co, Ltd, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Japanese Society of Laboratory Medicine Fund for Promotion of Scientific Research; grants from Japan Agency for Medical Research and Development during the conduct of the study; and personal fees from GlaxoSmithKline KK. K. Fukunaga reports grants from Japan Agency for Medical Research and Development during the conduct of the study. S. Konno reports grants from Japan Agency for Medical Research and Development during the conduct of the study; grants from AstraZeneca KK, Novartis Pharma KK, Nippon Boehringer Ingelheim Co, Ltd, and Japan Allergy Foundation; and grants from Kyorin Pharmaceutical Co, Ltd, outside the submitted work. H. Matsuse reports grants from Japan Agency for Medical Research and Development, during the conduct of the study; personal fees from Novartis, MSD KK, AstraZeneca KK, Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, and GlaxoSmithKline KK; and personal fees from Kyorin Pharmaceutical Co, Ltd, outside the submitted work. K. Kamei reports grants from Japan Agency for Medical Research and Development, during the conduct of the study. M. Taniguchi reports grants from Japan Agency for Medical Research and Development during the conduct of the study. T. Shimoda reports grants from Japan Agency for Medical Research and Development during the conduct of the study. T. Oguma reports grants from Japan Agency for Medical Research and Development during the conduct of the study. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This study was funded by the Research Grant on Allergic Disease and Immunology, from the Japan Agency for Medical Research and Development, under the grant numbers JP18ek0410026 and JP20ek0410055. Disclosure of potential conflict of interest: K. Asano reports grants from Japan Agency for Medical Research and Development; personal fees from Thermo Fisher Diagnostics KK during the conduct of the study; personal fees from AstraZeneca KK GlaxoSmithKline KK, and Teijin Pharma Ltd; grants and personal fees from Nippon Boehringer Ingelheim Co, Ltd and Novartis Pharma KK; and grants and personal fees from Sanofi SA outside the submitted work. A. Hebisawa reports grants from Japan Agency for Medical Research and Development during the conduct of the study. J. Suzuki reports grants from Japan Agency for Medical Research and Development during the conduct of the study. Y. Fukutomi reports grants from Japan Agency for Medical Research and Development during the conduct of the study; personal fees from Thermo Fisher Diagnostics KK, Torii Pharmaceutical Co, Ltd, and Kyorin Pharmaceutical Co, Ltd; grants and personal fees from Novartis Pharma KK; and grants from GlaxoSmithKline KK outside the submitted work. S. Ueki reports grants and personal fees from Novartis Pharma KK, AstraZeneca KK, and Sanofi; grants from Japan Allergy Foundation, Charitable Trust Laboratory Medicine Research Foundation of Japan, Japan Society for the Promotion of Science Kakenhi, Maruho Co, Ltd, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Japanese Society of Laboratory Medicine Fund for Promotion of Scientific Research; grants from Japan Agency for Medical Research and Development during the conduct of the study; and personal fees from GlaxoSmithKline KK. K. Fukunaga reports grants from Japan Agency for Medical Research and Development during the conduct of the study. S. Konno reports grants from Japan Agency for Medical Research and Development during the conduct of the study; grants from AstraZeneca KK, Novartis Pharma KK, Nippon Boehringer Ingelheim Co, Ltd, and Japan Allergy Foundation; and grants from Kyorin Pharmaceutical Co, Ltd, outside the submitted work. H. Matsuse reports grants from Japan Agency for Medical Research and Development, during the conduct of the study; personal fees from Novartis, MSD KK, AstraZeneca KK, Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, and GlaxoSmithKline KK; and personal fees from Kyorin Pharmaceutical Co, Ltd, outside the submitted work. K. Kamei reports grants from Japan Agency for Medical Research and Development, during the conduct of the study. M. Taniguchi reports grants from Japan Agency for Medical Research and Development during the conduct of the study. T. Shimoda reports grants from Japan Agency for Medical Research and Development during the conduct of the study. T. Oguma reports grants from Japan Agency for Medical Research and Development during the conduct of the study. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2020 The Authors
PY - 2021/4
Y1 - 2021/4
N2 - Background: There are several clinical diagnostic criteria for allergic bronchopulmonary aspergillosis (ABPA). However, these criteria have not been validated in detail, and no criteria for allergic bronchopulmonary mycosis (ABPM) are currently available. Objective: This study proposes new diagnostic criteria for ABPA/ABPM, consisting of 10 components, and compares its sensitivity and specificity to existing methods. Methods: Rosenberg-Patterson criteria proposed in 1977, the International Society for Human and Animal Mycology (ISHAM) criteria proposed in 2013, and this new criteria were applied to 79 cases with pathological ABPM and the control population with allergic mucin in the absence of fungal hyphae (n = 37), chronic eosinophilic pneumonia (n = 64), Aspergillus-sensitized severe asthma (n = 26), or chronic pulmonary aspergillosis (n = 24). These criteria were also applied to the 179 cases with physician-diagnosed ABPA/ABPM in a nationwide Japanese survey. Results: The sensitivity for pathological ABPM with Rosenberg-Patterson criteria, ISHAM criteria, and this new criteria were 25.3%, 77.2%, and 96.2%, respectively. The sensitivity for physician-diagnosed ABPA/ABPM were 49.2%, 82.7%, and 94.4%, respectively. The areas under the curve for the receiver-operating characteristic curves were 0.85, 0.90, and 0.98, respectively. The sensitivity for ABPM cases that were culture-positive for non-Aspergillus fungi were 13.0%, 47.8%, and 91.3%, respectively. Conclusions: The new diagnostic criteria, compared with existing criteria, showed better sensitivity and specificity for diagnosing ABPA/ABPM.
AB - Background: There are several clinical diagnostic criteria for allergic bronchopulmonary aspergillosis (ABPA). However, these criteria have not been validated in detail, and no criteria for allergic bronchopulmonary mycosis (ABPM) are currently available. Objective: This study proposes new diagnostic criteria for ABPA/ABPM, consisting of 10 components, and compares its sensitivity and specificity to existing methods. Methods: Rosenberg-Patterson criteria proposed in 1977, the International Society for Human and Animal Mycology (ISHAM) criteria proposed in 2013, and this new criteria were applied to 79 cases with pathological ABPM and the control population with allergic mucin in the absence of fungal hyphae (n = 37), chronic eosinophilic pneumonia (n = 64), Aspergillus-sensitized severe asthma (n = 26), or chronic pulmonary aspergillosis (n = 24). These criteria were also applied to the 179 cases with physician-diagnosed ABPA/ABPM in a nationwide Japanese survey. Results: The sensitivity for pathological ABPM with Rosenberg-Patterson criteria, ISHAM criteria, and this new criteria were 25.3%, 77.2%, and 96.2%, respectively. The sensitivity for physician-diagnosed ABPA/ABPM were 49.2%, 82.7%, and 94.4%, respectively. The areas under the curve for the receiver-operating characteristic curves were 0.85, 0.90, and 0.98, respectively. The sensitivity for ABPM cases that were culture-positive for non-Aspergillus fungi were 13.0%, 47.8%, and 91.3%, respectively. Conclusions: The new diagnostic criteria, compared with existing criteria, showed better sensitivity and specificity for diagnosing ABPA/ABPM.
KW - Allergic bronchopulmonary aspergillosis
KW - Aspergillus
KW - IgE
KW - allergic bronchopulmonary mycosis
KW - diagnosis
KW - eosinophils
KW - fungus
KW - mucus plugs
KW - severe asthma with fungal sensitization
UR - http://www.scopus.com/inward/record.url?scp=85095112915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095112915&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2020.08.029
DO - 10.1016/j.jaci.2020.08.029
M3 - Article
C2 - 32920094
AN - SCOPUS:85095112915
SN - 0091-6749
VL - 147
SP - 1261-1268.e5
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -